Unknown PHASE1 INTERVENTIONAL 1-arm NCT06078982

Posterior-line Treatment With Disitamab Vedotin Plus PD-1 in Advanced HER2-low Expressing Gastric Cancer

Efficacy and Safety of Disitamab Vedotin Combined With PD-1 in Posterior Line Therapy of Advanced HER2-low Expressing Gastric Cancer

Sponsor: Shanghai East Hospital

Conditions Gastric Cancer HER2-low-expressing Gastric Cancer

Interventions Disitamab Vedotin Toripalimab

Updated 4 times since 2023 Last updated: Oct 9, 2023 Started: Jun 6, 2023 Primary completion: Aug 31, 2025 Completion: Aug 31, 2025

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE1 clinical study on Gastric Cancer and HER2-low-expressing Gastric Cancer, this trial is ongoing. The trial is conducted by Shanghai East Hospital and has accumulated 4 data snapshots since 2023. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Status Flow

Change History

4 versions recorded

Dec 2025 — Present [monthly]

Unknown PHASE1

Status: Recruiting → Unknown
Sep 2024 — Dec 2025 [monthly]

Recruiting PHASE1
Jul 2024 — Sep 2024 [monthly]

Recruiting PHASE1
Nov 2023 — Jul 2024 [monthly]

Recruiting PHASE1

First recorded

Jun 2023

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Shanghai East Hospital

Data source: Shanghai East Hospital

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Shanghai, China